1975
Patterns of involvement with malignant lymphoma and implications for treatment decision making.
Johnson R, DeVita V, Kun L, Chabner B, Chretien P, Berard C, Johnson S. Patterns of involvement with malignant lymphoma and implications for treatment decision making. British Journal Of Cancer. Supplement 1975, 2: 237-41. PMID: 1182071, PMCID: PMC2149575.Peer-Reviewed Original ResearchConceptsMalignant lymphomaTreatment decisionsPresentation of lymphomaPrimary extranodal lymphomaMajority of patientsUntreated malignant lymphomaPattern of involvementMajority of casesLymphatic irradiationProspective stagingSurgical stagingExtranodal lymphomaExtranodal sitesHaematogenous spreadSystemic treatmentClinical courseConsecutive patientsLymph nodesDisease extentHodgkin's diseaseDisseminated involvementAppropriate treatmentLymphatic extensionPrimary manifestationHigh dose
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapy